Pericarditis Market Research Report— Global Forecast till 2027

Global Pericarditis Market Research Report: Information by Type (Acute Pericarditis, Recurrent Pericarditis and Chronic Pericarditis), Diagnosis & Treatment [Diagnosis (Electrocardiogram (ECG), Echocardiogram, Computerized Tomography (CT) and X-Ray) and Treatment (Medication (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Colchicine) and Surgical Treatment), End User (Hospitals & Clinics and Medical Institutes & Research Laboratories) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast til...

ID: MRFR/Pharma/1315-CR | August 2019 | Region: Global | 156 Pages         

1 Report Prologue

2 Market Introduction

2.1 Scope of the Study 17

2.2 List of Assumptions 17

2.3 Market Structure 18

3 Research Methodology

3.1 Research Process 20

3.2 Primary Research 21

3.3 Secondary Research 22

3.4 Market Size Estimation 23

3.5 Forecast Model 23

4 Market Dynamics

4.1 Introduction 25

4.2 Drivers 25

4.2.1 Increasing Prevalence of Cardiovascular Diseases Such as Heart Attack & Hypertension 25

4.2.2 Favorable Reimbursement Policies 26

4.2.3 Increasing Preference for Minimally Invasive Procedures 26

4.3 Restraints 26

4.3.1 Side-Effects of Anti-Inflammatory Drugs 26

4.3.2 Risk of Bacterial Infections 27

4.4 Opportunity 27

4.4.1 Robot-Assisted Surgery Will be a Technological Milestone 27

4.5 Challenges 27

4.5.1 Expiration of Blockbuster Drugs 27

4.6 Macroeconomic Indicators 28

4.7 Technological Trends & Assessments 28

5 Market Factor Analysis

5.1 Porter’s Five Forces Analysis 30

5.1.1 Bargaining Power of Suppliers 30

5.1.2 Bargaining Power of Buyers 31

5.1.3 Threat of New Entrants 31

5.1.4 Threat of Substitutes 31

5.1.5 Intensity of Rivalry 31

5.2 Supply Chain Analysis 32

5.2.1 R&D 32

5.2.2 Manufacturing 32

5.2.3 Distribution 32

5.2.4 Marketing & Sales 32

5.2.5 Post-Sales Monitoring 33

5.3 Investment Feasibility Analysis 33

6 Pericarditis Market, by Type

6.1 Introduction 35

6.2 Acute Pericarditis 36

6.3 Recurrent Pericarditis 37

6.4 Chronic Pericarditis 38

7 Pericarditis Market, by Diagnosis & Treatment

7.1 Introduction 40

7.2 Diagnosis 41

7.2.1 Electrocardiogram (ECG) 42

7.2.2 Echocardiogram 43

7.2.3 Computerized tomography (CT) 43

7.2.4 X-Ray 44

7.3 Treatment 45

7.3.1 Medication 46

7.3.1.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 47

7.3.1.2 Colchicine 47

7.3.2 Surgical Treatment 48

8 Pericarditis Market, by End User

8.1 Introduction 50

8.2 Hospitals & Clinics 51

8.3 Medical Institutes & Research laboratories 52

9 Global Pericarditis Market, By Region

9.1 Introduction 54

9.2 Americas 56

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.2.1 North America 60

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.2.1.1 US 63

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.2.1.2 Canada 66

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.2.2 South America 68

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.3 Europe 72

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.3.1 Western Europe 75

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.3.1.1 Germany 79

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.3.1.2 France 81

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.3.1.3 UK 84

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.3.1.4 Italy 86

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.3.1.5 Spain 89

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.3.1.6 Rest of Western Europe 91

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.3.2 Eastern Europe 94

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.4 Asia-Pacific 97

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.4.1 Japan 100

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.4.2 China 102

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.4.3 India 105

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.4.4 Australia 108

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.4.5 South Korea 111

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.4.6 Rest of Asia-Pacific 114

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.5 Middle East & Africa 117

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.5.1 Middle East 121

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

9.5.2 Africa 124

Pericarditis Market, by Type

Pericarditis Market, by Diagnosis & Treatment

Pericarditis Market, by End User

10 Competitive Landscape

10.1 Introduction 128

10.2 Company Ranking 128

11 Company Profile

11.1 Pfizer Inc. 130

11.1.1 Company Overview 130

11.1.2 Financial Overview 130

11.1.3 Products/Services Offered 131

11.1.4 Key Developments 131

11.1.5 SWOT Analysis 131

11.1.6 Key Strategies 132

11.2 AstraZeneca Plc 133

11.2.1 Company Overview 133

11.2.2 Financial Overview 133

11.2.3 Products/Services Offered 134

11.2.4 Key Developments 134

11.2.5 SWOT Analysis 134

11.2.6 Key Strategies 134

11.3 Bayer AG 135

11.3.1 Company Overview 135

11.3.2 Financial Overview 135

11.3.3 Products/Services Offered 136

11.3.4 Key Developments 136

11.3.5 SWOT Analysis 136

11.3.6 Key Strategies 136

11.4 Reckitt Benckiser Group Plc. 137

11.4.1 Company Overview 137

11.4.2 Financial Overview 137

11.4.3 Products/Services Offered 138

11.4.4 Key Developments 138

11.4.5 SWOT Analysis 138

11.4.6 Key Strategies 138

11.5 PerkinElmer, Inc. 139

11.5.1 Company Overview 139

11.5.2 Financial Overview 139

11.5.3 Products/Services Offered 140

11.5.4 Key Developments 140

11.5.5 SWOT Analysis 140

11.5.6 Key Strategies 140

11.6 Novartis International AG 141

11.6.1 Financial Overview 141

11.6.2 Products/Services Offered 142

11.6.3 Key Developments 142

11.6.4 SWOT Analysis 142

11.6.5 Key Strategies 142

11.7 FUJIFILM Holdings Corporation 143

11.7.1 Company Overview 143

11.7.2 Financial Overview 143

11.7.3 Products/Services Offered 144

11.7.4 Key Developments 144

11.7.5 SWOT Analysis 144

11.7.6 Key Strategies 144

11.8 Allergan plc. 145

11.8.1 Company Overview 145

11.8.2 Financial Overview 145

11.8.3 Products/Services Offered 146

11.8.4 SWOT Analysis 146

11.8.5 Key Developments 146

11.8.6 Key Strategies 146

11.9 Merck & Co., Inc. 147

11.9.1 Company Overview 147

11.9.2 Financial Overview 147

11.9.3 Products/Services Offered 148

11.9.4 Key Developments 148

11.9.5 SWOT Analysis 148

11.9.6 Key Strategies 148

11.10 Sanofi 149

11.10.1 Company Overview 149

11.10.2 Financial Overview 149

11.10.3 Products/Services Offered 150

11.10.4 Key Developments 150

11.10.5 SWOT Analysis 150

11.10.6 Key Strategies 150

11.11 Johnson & Johnson Services, Inc. 151

11.11.1 Company Overview 151

11.11.2 Financial Overview 151

11.11.3 Products/Services Offered 152

11.11.4 Key Developments 152

11.11.5 SWOT Analysis 152

11.11.6 Key Strategies 152

12 Appendix

12.1 Discussion Blue Print 154

13 List of Tables

TABLE 1 MARKET SYNOPSIS 15

TABLE 2 LIST OF ASSUMPTIONS 17

TABLE 3 GLOBAL PERICARDITIS MARKET, BY TYPE 2020–2027 (USD MILLION) 35

TABLE 4 GLOBAL PERICARDITIS MARKET FOR ACUTE PERICARDITIS, BY REGION 2020–2027 (USD MILLION) 36

TABLE 5 GLOBAL PERICARDITIS MARKET FOR ACUTE PERICARDITIS, BY REGION 2020–2027 (USD MILLION) 37

TABLE 6 GLOBAL PERICARDITIS MARKET FOR ACUTE PERICARDITIS, BY REGION 2020–2027 (USD MILLION) 38

TABLE 7 GLOBAL PERICARDITIS MARKET, BY DIAGNOSIS & TREATMENT 2020–2027 (USD MILLION) 40

TABLE 8 GLOBAL PERICARDITIS MARKET FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 41

TABLE 9 GLOBAL PERICARDITIS MARKET FOR DIAGNOSIS, BY REGION 2020–2027 (USD MILLION) 41

TABLE 10 GLOBAL PERICARDITIS MARKET FOR ELECTROCARDIOGRAM (ECG), BY REGION 2020–2027 (USD MILLION) 42

TABLE 11 GLOBAL PERICARDITIS MARKET FOR ECHOCARDIOGRAM, BY REGION 2020–2027 (USD MILLION) 43

TABLE 12 GLOBAL PERICARDITIS MARKET FOR CT, BY REGION 2020–2027 (USD MILLION) 43

TABLE 13 GLOBAL PERICARDITIS MARKET FOR X-RAY, BY REGION 2020–2027 (USD MILLION) 44

TABLE 14 GLOBAL PERICARDITIS MARKET FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 45

TABLE 15 GLOBAL PERICARDITIS MARKET FOR TREATMENT, BY REGION 2020–2027 (USD MILLION) 45

TABLE 16 GLOBAL PERICARDITIS MARKET FOR MEDICATION, BY TYPE 2020–2027 (USD MILLION) 46

TABLE 17 GLOBAL PERICARDITIS MARKET FOR MEDICATION, BY REGION 2020–2027 (USD MILLION) 46

TABLE 18 GLOBAL PERICARDITIS MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION 2020–2027 (USD MILLION) 47

TABLE 19 GLOBAL PERICARDITIS MARKET FOR COLCHICINE, BY REGION 2020–2027 (USD MILLION) 47

TABLE 20 GLOBAL PERICARDITIS MARKET FOR SURGICAL TREATMENT, BY REGION 2020–2027 (USD MILLION) 48

TABLE 21 GLOBAL PERICARDITIS MARKET, BY END-USER 2020–2027 (USD MILLION) 50

TABLE 22 GLOBAL PERICARDITIS MARKET FOR HOSPITALS & CLINICS, BY REGION 2020–2027 (USD MILLION) 51

TABLE 23 GLOBAL PERICARDITIS MARKET FOR MEDICAL INSTITUTES & RESEARCH LABORATORIES, BY REGION 2020–2027 (USD MILLION) 52

TABLE 24 GLOBAL PERICARDITIS MARKET, BY REGION 2020–2027 (USD MILLION) 55

TABLE 25 AMERICAS PERICARDITIS MARKET BY REGION, 2020–2027 (USD MILLION) 56

TABLE 26 AMERICAS PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 27 AMERICAS PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 57

TABLE 28 AMERICAS PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 58

TABLE 29 AMERICAS PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 58

TABLE 30 AMERICAS PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 59

TABLE 31 AMERICAS PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 59

TABLE 32 NORTH AMERICA PERICARDITIS MARKET BY COUNTRY, 2020–2027 (USD MILLION) 60

TABLE 33 NORTH AMERICA PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 34 NORTH AMERICA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 61

TABLE 35 NORTH AMERICA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 61

TABLE 36 NORTH AMERICA PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 61

TABLE 37 NORTH AMERICA PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 62

TABLE 38 NORTH AMERICA PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 62

TABLE 39 US PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 40 US PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 63

TABLE 41 US PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 63

TABLE 42 US PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 64

TABLE 43 US PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 64

TABLE 44 US PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 65

TABLE 45 CANADA PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 46 CANADA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 66

TABLE 47 CANADA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 66

TABLE 48 CANADA PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 67

TABLE 49 CANADA PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 67

TABLE 50 CANADA PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 68

TABLE 51 SOUTH AMERICA PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 52 SOUTH AMERICA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 69

TABLE 53 SOUTH AMERICA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 69

TABLE 54 SOUTH AMERICA PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 70

TABLE 55 SOUTH AMERICA PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 70

TABLE 56 SOUTH AMERICA PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 71

TABLE 57 EUROPE PERICARDITIS MARKET BY REGION, 2020–2027 (USD MILLION) 72

TABLE 58 EUROPE PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 59 EUROPE PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 73

TABLE 60 EUROPE PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 73

TABLE 61 EUROPE PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 74

TABLE 62 EUROPE PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 74

TABLE 63 EUROPE PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 75

TABLE 64 WESTERN EUROPE PERICARDITIS MARKET BY COUNTRY, 2020–2027 (USD MILLION) 76

TABLE 65 WESTERN EUROPE PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 66 WESTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 77

TABLE 67 WESTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 77

TABLE 68 WESTERN EUROPE PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 77

TABLE 69 WESTERN EUROPE PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 78

TABLE 70 WESTERN EUROPE PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 78

TABLE 71 GERMANY PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 72 GERMANY PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 79

TABLE 73 GERMANY PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 79

TABLE 74 GERMANY PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 80

TABLE 75 GERMANY PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 80

TABLE 76 GERMANY PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 81

TABLE 77 FRANCE PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 78 FRANCE PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 81

TABLE 79 FRANCE PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 82

TABLE 80 FRANCE PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 82

TABLE 81 FRANCE PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 83

TABLE 82 FRANCE PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 83

TABLE 83 UK PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 84 UK PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 84

TABLE 85 UK PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 84

TABLE 86 UK PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 85

TABLE 87 UK PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 85

TABLE 88 UK PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 86

TABLE 89 ITALY PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 86

TABLE 90 ITALY PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 86

TABLE 91 ITALY PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 87

TABLE 92 ITALY PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 87

TABLE 93 ITALY PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 88

TABLE 94 ITALY PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 88

TABLE 95 SPAIN PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 96 SPAIN PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 89

TABLE 97 SPAIN PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 89

TABLE 98 SPAIN PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 90

TABLE 99 SPAIN PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 90

TABLE 100 SPAIN PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 91

TABLE 101 REST OF WESTERN EUROPE PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 102 REST OF WESTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 91

TABLE 103 REST OF WESTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 92

TABLE 104 REST OF WESTERN EUROPE PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 92

TABLE 105 REST OF WESTERN EUROPE PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 93

TABLE 106 REST OF WESTERN EUROPE PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 93

TABLE 107 EASTERN EUROPE PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 108 EASTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 94

TABLE 109 EASTERN EUROPE PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 95

TABLE 110 EASTERN EUROPE PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 95

TABLE 111 EASTERN EUROPE PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 96

TABLE 112 EASTERN EUROPE PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 96

TABLE 113 ASIA-PACIFIC PERICARDITIS MARKET BY COUNTRY, 2020–2027 (USD MILLION) 97

TABLE 114 ASIA-PACIFIC PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 115 ASIA-PACIFIC PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 98

TABLE 116 ASIA-PACIFIC PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 98

TABLE 117 ASIA-PACIFIC PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 99

TABLE 118 ASIA-PACIFIC PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 99

TABLE 119 ASIA-PACIFIC PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 100

TABLE 120 JAPAN PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 100

TABLE 121 JAPAN PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 100

TABLE 122 JAPAN PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 101

TABLE 123 JAPAN PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 101

TABLE 124 JAPAN PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 101

TABLE 125 JAPAN PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 102

TABLE 126 CHINA PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 102

TABLE 127 CHINA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 103

TABLE 128 CHINA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 103

TABLE 129 CHINA PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 103

TABLE 130 CHINA PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 104

TABLE 131 CHINA PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 104

TABLE 132 INDIA PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 105

TABLE 133 INDIA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 105

TABLE 134 INDIA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 106

TABLE 135 INDIA PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 106

TABLE 136 INDIA PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 106

TABLE 137 INDIA PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 107

TABLE 138 AUSTRALIA PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 108

TABLE 139 AUSTRALIA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 108

TABLE 140 AUSTRALIA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 109

TABLE 141 AUSTRALIA PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 109

TABLE 142 AUSTRALIA PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 109

TABLE 143 AUSTRALIA PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 110

TABLE 144 SOUTH KOREA PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 111

TABLE 145 SOUTH KOREA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 111

TABLE 146 SOUTH KOREA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 112

TABLE 147 SOUTH KOREA PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 112

TABLE 148 SOUTH KOREA PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 112

TABLE 149 SOUTH KOREA PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 113

TABLE 150 REST OF ASIA-PACIFIC PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 114

TABLE 151 REST OF ASIA-PACIFIC PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 114

TABLE 152 REST OF ASIA-PACIFIC PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 115

TABLE 153 REST OF ASIA-PACIFIC PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 115

TABLE 154 REST OF ASIA-PACIFIC PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 115

TABLE 155 REST OF ASIA-PACIFIC PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 116

TABLE 156 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY REGION, 2020–2027 (USD MILLION) 117

TABLE 157 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 118

TABLE 158 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 118

TABLE 159 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 118

TABLE 160 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 119

TABLE 161 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 119

TABLE 162 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 120

TABLE 163 MIDDLE EAST PERICARDITIS MARKET BY TYPE, 2020–2027 (USD MILLION) 121

TABLE 164 MIDDLE EAST PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 121

TABLE 165 MIDDLE EAST PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 122

TABLE 166 MIDDLE EAST PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 122

TABLE 167 MIDDLE EAST PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 122

TABLE 168 MIDDLE EAST PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 123

TABLE 169 AFRICA PERICARDITIS MARKET BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 124

TABLE 170 AFRICA PERICARDITIS MARKET BY DIAGNOSIS TYPE, 2020–2027 (USD MILLION) 125

TABLE 171 AFRICA PERICARDITIS MARKET BY TREATMENT TYPE, 2020–2027 (USD MILLION) 125

TABLE 172 AFRICA PERICARDITIS MARKET BY MEDICATION TYPE, 2020–2027 (USD MILLION) 125

TABLE 173 AFRICA PERICARDITIS MARKET BY END-USER, 2020–2027 (USD MILLION) 126

TABLE 174 TOP MANUFACTURERS IN THE GLOBAL PERICARDITIS MARKET 128

14 List of Figures

FIGURE 1 GLOBAL PERICARDITIS MARKET: MARKET STRUCTURE 18

FIGURE 2 RESEARCH PROCESS OF MRFR 20

FIGURE 3 TOP-DOWN AND BOTTOM-UP APPROACHES 23

FIGURE 4 PORTER’S FIVE FORCES ANALYSIS OF THE GLOBAL PERICARDITIS MARKET 30

FIGURE 5 SUPPLY CHAIN: PERICARDITIS MARKET 32

FIGURE 6 GLOBAL PERICARDITIS MARKET, BY TYPE 2020 & 2027 35

FIGURE 7 GLOBAL PERICARDITIS MARKET, BY DIAGNOSIS & TREATMENT 2020 & 2027 40

FIGURE 8 GLOBAL PERICARDITIS MARKET, BY END-USER 2020 & 2027 50

FIGURE 9 GLOBAL PERICARDITIS MARKET BY REGION, 2020 & 2027 (USD MILLION) 54

FIGURE 10 AMERICAS PERICARDITIS MARKET, BY REGION, 2020 (%) 56

FIGURE 11 NORTH AMERICA PERICARDITIS MARKET BY REGION, 2020 (%) 60

FIGURE 12 EUROPE PERICARDITIS MARKET BY REGION, 2020 (%) 72

FIGURE 13 WESTERN EUROPE PERICARDITIS MARKET BY COUNTRY, 2020 (%) 75

FIGURE 14 ASIA-PACIFIC PERICARDITIS MARKET BY REGION, 2020 (%) 97

FIGURE 15 MIDDLE EAST & AFRICA PERICARDITIS MARKET BY REGION, 2020 (%) 117

Pericarditis Market Speak to Analyst Request a Free Sample

Overview


The Global Pericarditis Market is expected to register 7.96% CAGR and is anticipated to reach USD 2,741.39 Million by 2023.


Pericarditis is inflammation of the pericardium (the fibrous sac surrounding the heart). Symptoms typically include a sudden onset of sharp chest pain. The pain may also be felt in the shoulders, neck, or back. It generally is better sitting up and worse when lying down or breathing deeply.


The increasing prevalence of cardiovascular diseases such as heart attack & hypertension, favorable reimbursement policies, and increasing preference for minimally invasive procedures are the major drivers propelling market growth. However, the side-effects of anti-inflammatory drugs and the risk of bacterial infections constrain the growth of the pericarditis drugs market.


Market Dynamics


The prevalence of cardiovascular diseases is found to be increasing over the last decade. This is attributed to the rising incidences of chronic diseases such as obesity and diabetes, which are major risk factors for cardiovascular diseases such as pericarditis, heart attack, and hypertension. As per the American Heart Association, nearly 92.1 million Americans were diagnosed with cardiovascular diseases in 2017. Additionally, it also stated that the prevalence is found to be higher in men than in women. Furthermore, in the same year, more than 92% of the patients exhibited major symptoms of heart diseases such as chest pain, heartburns, and strokes.


Recently, the prevalence of cardiovascular diseases is found to be increasing from the last few years. The American Heart Association stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the people had hypertension.


Cardiovascular disease is one of the significant chronic disease responsible for a high death toll across the globe. This emphasizes the need for the development of new diagnostics and treatment devices around the world. The market is also affected by the increasing number of people diagnosed with these diseases at an early stage. Therefore, the prevalence of cardiovascular disease would drive the growth of the market during the forecast period.


The pericarditis drugs market is driven by the increasing number of patients suffering from cardiovascular diseases, thus signifying the need for the development of new technologically advanced devices for monitoring the heart rate. Continuous monitoring of cardiovascular diseases is an important aspect of cardiology. Therefore, the prevalence of pericarditis is increasing with a rise in the prevalence of cardiovascular diseases, fueling market growth.


Global Pericarditis Market Size, by End User, 2017 (USD Million)  Pericarditis Market


Source: MRFR Analysis


Segmentation


The global pericarditis market has been segmented into type, application, and end user. 


Based on type, the global pericarditis drugs market has been segmented acute pericarditis, recurrent pericarditis, and chronic pericarditis.


Based on diagnosis & treatment, the global market has been divided into diagnosis and treatment. The diagnosis segment is further divided into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), X-Ray. The treatment segment is bifurcated into medication (non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine) and surgical treatment.


Based on end user, the global market has been segmented into hospitals & clinics and medical institutes & research laboratories. The hospitals & clinics segment accounted for a market value of USD 840.30 million in 2017.


Key Players


The prominent players in the global pericarditis market are Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are the top five market players in this market. Apart from these, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc. are some of the other major players in the global market.


Some of the key strategies followed by the players operating in the global pericarditis market are innovation, product development, acquisition, and expansion.


Asia-Pacific Pericarditis Market Share, by Country, 2017 (%)  Pericarditis Market


Source: MRFR Analysis


Regional Analysis


The global pericarditis market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The Americas is estimated to dominate the global pericarditis drugs market during the forecast period. This is attributed to the rising investments in research and development owing to investments in reputed research centers and government institutions and increasing expenditure on healthcare play a vital role in the growth of the regional market. Besides, several research grants are given by governmental agencies.


The European market for pericarditis is expected to be the second-largest during the forecast period. The presence of medical device companies, the rising burden of rheumatoid arthritis (RA), and growing healthcare spending are expected to boost the growth of the market in this region. Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth.


Asia-Pacific is estimated to be the fastest-growing market due to the growing geriatric population, rapid developments in technology. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the region, China accounted for a market share of 24.6% in 2017.


Furthermore, the market in the Middle East & Africa is expected to witness slow growth due to limited access to healthcare facilities.


Key Updates



  • In July 2017, Pfizer Inc. extended the collaboration with Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.



  • In October 2018, Reckitt Benckiser (RB) launched a 24-hour pain relief patch along with a campaign to educate patients about pain to encourage patients to facilitate pain management.



  • In October 2018, FUJIFILM Medical Systems USA, Inc., a provider of diagnostic imaging and medical informatics solutions launched the FCT Embrace wide bore computed tomography (CT) imaging unit in the US, thereby entering into the US computed tomography market.


Market Segmentation


Global Pericarditis Market, by Type



  • Acute Pericarditis

  • Recurrent Pericarditis

  • Chronic Pericarditis


Global Pericarditis Market, by Diagnosis & Treatment



  • Diagnosis

  • Electrocardiogram (ECG),

  • Echocardiogram,

  • Computerized Tomography (CT)

  • X-Ray

  • Treatment

  • Medication

  • Surgical Treatment


Global Pericarditis Market, by End User



  • Hospitals & Clinics

  • Medical Institutes & Research laboratories


Global Pericarditis Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Available Additional Customizations



  • Pricing Analysis

  • Competitive Benchmarking for Global Pericarditis Market


Intended Audience



  • Medical device manufacturers and distributors

  • Government research organizations

  • Hospitals and clinics

  • Regulatory agencies

  • Pharmaceutical companies



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 2,741.39 Million
  CAGR   7.96%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, application, and end user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are the top five market players in this market. Apart from these, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc.
  Key Market Opportunities   Development of new diagnostics and treatment devices
  Key Market Drivers   Rising preference for minimally invasive diagnostic and treatment procedures and the popularity of robot-assisted cardiac surgeries


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Pericarditis market projected to grow at approximately 7.96% CAGR during the assessment period (2017-2023).

The valuation of the global pericarditis market is estimated to increase to USD 2,741.39 MN by the end of 2023.

On the basis of type, acute pericarditis holds majority shares in the global pericarditis market.

Rising preference for minimally invasive diagnostic and treatment procedures and the popularity of robot-assisted cardiac surgeries are major tailwinds pushing the growth of the global pericarditis market.

North America holds the largest share in the global pericarditis market, followed by Europe and the Asia Pacific, respectively.

Sakura Finetek USA, Inc. (U.S.), Hitachi High-Technologies Corporation (Japan), Leica Biosystems Nussloch GmbH (Germany), Euromex Microscopen BV (The Netherlands), ZEISS International (Germany), Celestron LLC (U.S.), Labomed, Inc. (U.S.), Olympus Corporation (Japan), Bruker Corporation (U.S.), and Nikon Corporation (Japan), are some of the top players operating in the global pericarditis market.

Global Pericarditis Market: Company Landscape


The Global pericarditis market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive with all the players competing to gain the market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, quality, and reliability. It is decisive for vendors to provide cost-efficient and high-quality products, to survive and succeed in an intensely competitive and growing market environment.


The growth of market vendors is dependent on market conditions, government support, and industry development. Thus, vendors should focus on expanding geographically and improving their products. They primarily focus on the development of novel products. Although international players are dominating the market, regional and foreign players with small market shares also have a presence. The international players are likely to strengthen their presence worldwide through acquisitions during the forecast period. It has also been forecast that improvement of the global economic scenario combined with efforts to enhance infrastructure in emerging nations, is fueling the market growth, thereby making it an ideal time for new products and to increase the global market share.


Many leading players are concentrated in the Americas owing to the strengthening healthcare system, well-established market, high healthcare expenditures, and numerous opportunities for growth. These players have expanded their market in other regions as well. Furthermore, companies such as Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are top five market players in this market. Apart from this, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc. are some of the well-established players in the global pericarditis market.


Pfizer Inc. (Pfizer) is a leading research-based biopharmaceutical company that develops medicines and vaccines for a wide range of medical disciplines including cardiology, immunology, oncology, diabetology/endocrinology, and neurology. Pfizer additionally teams up with healthcare providers, governments, and local communities to support and expand access to reliable and affordable healthcare around the world. The company operates worldwide in the Americas, Europe, Asia-Pacific, and the Middle East and Africa.  In July 2017 Pfizer Inc. extended the collaboration with Catalent, Inc, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.


Novartis International AG (Novartis) is a Swiss multinational pharmaceutical company that researches, develops, manufactures, and distributes a wide range of healthcare products globally. The company operates through three segments, namely, innovative medicines, Sandoz, and Alcon. The company provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory diseases.


Allergan plc. (Allergan) is a pharmaceutical company with a motive of manufacturing, developing, and commercializing pharmaceutical products, biological products, and devices for patients worldwide. The company has a wide range of products which provide effective treatments for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories. The company has operations across the globe in regions such as Europe, Africa, Americas, and Asia-Pacific.


Merck & Co., Inc. (Merck) is also known as MSD outside the US and Canada. The company operates through its four segments, namely, pharmaceutical, animal health, healthcare services, and alliances. The company offers therapeutic and preventive agents to treat arthritis and pain, cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, and other diseases. Merck works with clients and works in more than 140 countries to provide inventive healthcare products.